Business
AZN: H1 2018 Results
AZN: H1 2018 Results.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 7978V AstraZeneca PLC 26 July 2018 \n\nAstraZeneca PLC\n26 July 2018 07:00 BST\nH1 2018 Results\n \nStrong performances from new medicines and Emerging Markets underpin the return to growth in 2018\n \nOver the first half, the strong sales growth from new medicines (+75%, +69% at CER1) and the continued strength of the Emerging Markets business (+14%, +10% at CER) were offset by the impact from the loss of Crestor exclusivity in Europe and Japan. In line with expectations, an improved performance is anticipated in the second half, notably Product Sales, where guidance is reiterated for a low single-digit percentage increase over the full year at CER. Important news flow from the pipeline is expected to continue beyond the rest of the year.\n \nFinancial Highlights\n\n\n\n\n \n \n\n\nH1 2018\n\n\nQ2 2018\n\n\n\n\n$m\n\n\n% change\n\n\n$m\n\n\n% change\n\n\n\n\n \n\n\nActual\n\n\nCER\n\n\nActual\n\n\nCER\n\n\n\n\nTotal Revenue\n\n\n10,333\n\n\n(1)\n\n\n(5)\n\n\n5,155\n\n\n2\n\n\n(1)\n\n\n\n\nProduct Sales\n\n\n10,015\n\n\n2\n\n\n(2)\n\n\n5,030\n\n\n2\n\n\n(1)\n\n\n\n\nExternalisation Revenue\n\n\n318\n\n\n(53)\n\n\n(54)\n\n\n125\n\n\n14\n\n\n14\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n\n\nReported Operating Profit2\n\n\n1,459\n\n\n(21)\n\n\n(20)\n\n\n763\n\n\n(17)\n\n\n(20)\n\n\n\n\nCore Operating Profit3\n\n\n2,161\n\n\n(33)\n\n\n(34)\n\n\n1,265\n\n\n(18)\n\n\n(22)\n\n\n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n \n\n\n\n\nReported Earnings Per Share (EPS)\n\n\n$0.54\n\n\n(32)\n\n\n(34)\n\n\n$0.27\n\n\n(27)\n\n\n(38)\n\n\n\n\nCore EPS\n\n\n$1.17\n\n\n(37)\n\n\n(39)\n\n\n$0.69\n\n\n(21)\n\n\n(26)\n\n\n\n\n \n• Product Sales increased by 2% (down by 2% at CER) to $10,015m. New medicines4 generated more than $1bn in additional sales at CER in the half\n \n• The Reported Gross Margin declined by three percentage points to 78.6%, reflecting the favourable impact of manufacturing variances realised in H1 2017 and the agreement on Lynparza with MSD5; the Core Gross Margin fell by three percentage points to 80.0%\n \n• Productivity gains and cost discipline continued with prioritised and targeted investment in ...